Tandem Diabetes Care to Announce Q1 2026 Results on May 7

The insulin delivery tech company will hold a conference call to discuss its first quarter 2026 financial and operating results.

Apr. 2, 2026 at 8:06pm

Got story updates? Submit your updates here. ›

A high-contrast, cinematic close-up image of the internal gears, circuits, and components that make up the inner workings of a modern insulin pump device, rendered in a heavy industrial style reminiscent of the photography of Margaret Bourke-White.An extreme close-up of the intricate inner workings of an advanced insulin delivery system highlights the technical complexity behind modern diabetes management technology.San Diego Today

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, plans to release its first quarter 2026 results after the financial markets close on Thursday, May 7, 2026. The company will hold a conference call and simultaneous webcast on the same day to discuss its Q1 2026 financial and operating results.

Why it matters

As a major player in the insulin delivery and diabetes tech space, Tandem's quarterly results provide insights into the performance and direction of the broader industry. The company's advanced automated insulin delivery systems are aimed at reducing the burden of diabetes management for patients.

The details

Tandem Diabetes Care will release its Q1 2026 results on May 7, 2026 after market close. The company will then hold a conference call and webcast at 4:30pm ET (1:30pm PT) to discuss the financial and operating results for the quarter.

  • Tandem Diabetes Care will release its Q1 2026 results on May 7, 2026 after market close.
  • The company will hold a conference call and webcast at 4:30pm ET (1:30pm PT) on May 7, 2026 to discuss the Q1 2026 results.

The players

Tandem Diabetes Care, Inc.

A global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems.

Got photos? Submit your photos here. ›

What’s next

Investors and analysts will be listening closely to Tandem's Q1 2026 conference call for updates on the company's financial performance, product pipeline, and market positioning within the insulin delivery and diabetes tech space.

The takeaway

Tandem Diabetes Care's quarterly results provide important insights into the state of the insulin delivery and diabetes technology industry. As a leader in this space, the company's performance and outlook can signal broader trends and opportunities for patients, healthcare providers, and investors.